Literature DB >> 6689118

Allopurinol metabolism in a patient with xanthine oxidase deficiency.

H Yamanaka, K Nishioka, T Suzuki, K Kohno.   

Abstract

A patient with complete deficiency of xanthine oxidase would not be expected to oxidase allopurinol to oxipurinol if allopurinol did not have any alternative metabolic pathway. 400 mg of allopurinol was administered to a patient with xanthine oxidase deficiency, and plasma allopurinol, oxipurinol, hypoxanthine, and xanthine levels were determined serially by the use of high-performance liquid chromatography (HPLC). Plasma oxipurinol as well as allopurinol was increased after the administration of allopurinol, and oxipurinol reached a maximum level of 13.1 micrograms/ml at 6 hours after the administration. This was the same pattern as that of normal controls. This result demonstrated the existence of some other oxidising enzyme of allopurinol than xanthine oxidase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6689118      PMCID: PMC1001330          DOI: 10.1136/ard.42.6.684

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Xanthine oxidase deficiency: studies of a previously unreported case.

Authors:  E W Holmes; D H Mason; L I Goldstein; R E Blount; W N Kelley
Journal:  Clin Chem       Date:  1974-08       Impact factor: 8.327

3.  Variations in allopurinol metabolism by xanthinuric subjects.

Authors:  H A Simmonds; B Levin; J S Cameron
Journal:  Clin Sci Mol Med       Date:  1974-08

4.  Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol.

Authors:  H A Simmonds
Journal:  Clin Chim Acta       Date:  1969-02       Impact factor: 3.786

5.  The determination of allopurinol and oxipurinol in human plasma and urine.

Authors:  M Brown; A Bye
Journal:  J Chromatogr       Date:  1977-03-01

6.  [A case of asymptomatic xanthine oxidase deficiency (author's transl)].

Authors:  T Katsuki; T Shimizu; T Nishina; K Fujihira; K Nishioka; T Ohsawa
Journal:  Nihon Naika Gakkai Zasshi       Date:  1981-09-10

7.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

8.  Formation of nucleotides of (6-14C)allopurinol and (6-14C)oxipurinol in rat tissues and effects on uridine nucleotide pools.

Authors:  D J Nelson; C J Buggé; H C Krasny; G B Elion
Journal:  Biochem Pharmacol       Date:  1973-08-15       Impact factor: 5.858

9.  Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates.

Authors:  D G Johns
Journal:  J Clin Invest       Date:  1967-09       Impact factor: 14.808

10.  The conversion of 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) into 4,6-dihroxypyrazolo[3,4-d]pyrimidine (Oxipurinol) in vivo in the absence of xanthine-oxen oxidoreductase.

Authors:  R A Chalmers; R Parker; H A Simmonds; W Snedden; R W Watts
Journal:  Biochem J       Date:  1969-05       Impact factor: 3.857

View more
  1 in total

Review 1.  Allopurinol, uric acid, and oxidative stress in cardiorenal disease.

Authors:  Markus Riegersperger; Adrian Covic; David Goldsmith
Journal:  Int Urol Nephrol       Date:  2011-03-10       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.